{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T23:11:57Z","timestamp":1768345917992,"version":"3.49.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bergen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We investigated sensitivity of the 2020 Revised Comprehensive Diagnostic Criteria (RCD) and the 2019 ACR\/EULAR classification criteria across the four identified IgG4-related disease (IgG4-RD) phenotypes: \u201cPancreato-Hepato-Biliary\u201d, \u201cRetroperitoneum and Aorta\u201d, \u201cHead and Neck-limited\u201d and \u201cMikulicz\u2019 and Systemic\u201d in a well-characterized patient cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We included adult patients diagnosed with IgG4-RD after comprehensive clinical assessment at Oslo University Hospital in Norway. We assigned patients to IgG4-RD phenotypes based on pattern of organ involvement and assessed fulfillment of RCD and 2019 ACR\/EULAR classification criteria. Differences between phenotype groups were analyzed using one-way ANOVA for continuous variables, and contingency tables for categorical variables.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study cohort included 79 IgG4-RD patients assigned to the \u201cPancreato-Hepato-Biliary\u201d (22.8%), Retroperitoneum and Aorta\u201d (22.8%) \u201cHead and Neck-limited\u201d (29.1%), and \u201cMikulicz\u2019 and Systemic\u201d (25.3%) phenotype groups, respectively. While 7\ufeff2\/79 (91.1%) patients in total fulfilled the RCD, proportion differed across phenotype groups and was lowest in the \u201cRetroperitoneum and Aorta\u201d group (\ufeff66.7%, <jats:italic>p<\/jats:italic>\u2009&lt; 0.001). Among the 57 (72.2%) patients meeting the 2019 ACR\/EULAR classification criteria, proportion was again lowest in the \u201cRetroperitoneum and Aorta\u201d group (27.8%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The results from this study indicate that IgG4-RD patients having the \u201cRetroperitoneum and Aorta\u201d phenotype less often fulfill diagnostic criteria and classification criteria than patients with other IgG4-RD phenotypes. Accordingly, this phenotype is at risk of being systematically selected against in observational studies and randomized clinical trials, with potential implications for patients, caregivers and future definitions of IgG4-RD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-023-03155-y","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T07:01:49Z","timestamp":1693897309000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Differential sensitivity of the 2020 revised comprehensive diagnostic criteria and the 2019 ACR\/EULAR classification criteria across IgG4-related disease phenotypes: results from a Norwegian cohort"],"prefix":"10.1186","volume":"25","author":[{"given":"Jens","family":"Vikse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d8yvind","family":"Midtvedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f8rg-Tilde Svanes","family":"Fevang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torhild","family":"Garen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d8yvind","family":"Palm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Wallenius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnstein","family":"Bakland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrine Br\u00e6kke","family":"Norheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d8yvind","family":"Molberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Maria","family":"Hoffmann-Vold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"key":"3155_CR1","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMra1104650","volume":"366","author":"JH Stone","year":"2012","unstructured":"Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012;366:539\u201351.","journal-title":"N Engl J Med"},{"key":"3155_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1136\/annrheumdis-2019-216561","volume":"79","author":"ZS Wallace","year":"2020","unstructured":"Wallace ZS, Naden RP, Chari S, et al. The 2019 American college of rheumatology\/European league against rheumatism classification criteria for igg4-related disease. Ann Rheum Dis. 2020;79:77\u201387.","journal-title":"Ann Rheum Dis"},{"key":"3155_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3109\/s10165-011-0571-z","volume":"22","author":"H Umehara","year":"2012","unstructured":"Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012;22:21\u201330.","journal-title":"Mod Rheumatol"},{"issue":"3","key":"3155_CR4","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1080\/14397595.2020.1859710","volume":"31","author":"H Umehara","year":"2021","unstructured":"Umehara H, Okazaki K, Kawa S, et al. The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD. Mod Rheumatol. 2021;31(3):529\u201333.","journal-title":"Mod Rheumatol"},{"issue":"7","key":"3155_CR5","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/acr.22583","volume":"67","author":"R Aggarwal","year":"2015","unstructured":"Aggarwal R, Ringold S, Khanna D, et al. Distinctions between diagnostic and classification criteria? Arthritis Care Res (Hoboken). 2015;67(7):891\u20137.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3155_CR6","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/annrheumdis-2018-214603","volume":"78","author":"ZS Wallace","year":"2019","unstructured":"Wallace ZS, Zhang Y, Perugino CA, et al. Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. Ann Rheum Dis. 2019;78:406\u201312.","journal-title":"Ann Rheum Dis"},{"key":"3155_CR7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/rheumatology\/key285","volume":"58","author":"T Garen","year":"2019","unstructured":"Garen T, Lerang K, Hoffmann-Vold AM, et al. Mortality and causes of death across the systemic connective tissue diseases and the primary systemic vasculitides. Rheumatology (Oxford). 2019;58:313\u201320.","journal-title":"Rheumatology (Oxford)"},{"key":"3155_CR8","doi-asserted-by":"publisher","first-page":"m1067","DOI":"10.1136\/bmj.m1067","volume":"369","author":"M Lanzillotta","year":"2020","unstructured":"Lanzillotta M, Mancuso G, Della-Torre E. Advances in the diagnosis and management of IgG4 related disease. BMJ. 2020;369:m1067.","journal-title":"BMJ"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03155-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-023-03155-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03155-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T22:31:47Z","timestamp":1700260307000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-023-03155-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":8,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3155"],"URL":"https:\/\/doi.org\/10.1186\/s13075-023-03155-y","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,5]]},"assertion":[{"value":"12 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was given for the included IgG4-RD patients as requirement for inclusion in NOSVAR. The study was conducted in compliance with the Helsinki Declaration and approved by the regional ethics committee (REK #342136).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J.V. has been a speaker\/consultant of Boehringer Ingelheim, GSK, Novartis, Jupiter Life Science. B-T.S.F. has been a speaker\/consultant of Lilly, UCB. G.B. has been a speaker\/consultant of UCB. A-M.H-V. has been a speaker\/consultant of ARXX, Boehringer Ingelheim, Genentech, Jannsen, Medscape, Merck Sharp & Dohme, Roche, and received grant from Boehringer Ingelheim, Jannsen.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"163"}}